Top

International Urogynecology Journal

Published in:

01-12-2016 | Original Article

Quality of life outcomes in peri-urethral calcium hydroxylapatite injection

Authors: Meghan A. Griffin, Kirsten J. C. Janosek-Albright, Mireya Diaz-Insua, Solafa Elshatanoufy, Humphrey O. Atiemo

Published in: International Urogynecology Journal | Issue 12/2016

Abstract

Introduction and hypothesis

Peri-urethral calcium hydroxylapatite injection is an established treatment for patients with stress urinary incontinence. Information is limited regarding calcium hydroxylapatite treatment and quality of life (QOL) outcomes. We hypothesize that patients might improve QOL after peri-urethral calcium hydroxylapatite injection, which was reflected in validated questionnaires.

Methods

The peri-urethral calcium hydroxylapatite injection billing code was used to identify patients who underwent injection from 2011–2013. Female patients who completed the American Urological Association Symptom Score (AUASS), the AUASS QOL and Michigan Incontinence Symptom Index (M-ISI), and the bother score (M-ISI bother), or pad count at baseline and follow-up were included. Change in questionnaire scores and pads were assessed using the paired t test.

Results

Sixty patients underwent 1 (30), 2 (63) or 3 (7 %) peri-urethral calcium hydroxylapatite injections performed by a single surgeon. Thirty-seven patients provided questionnaires and 38 provided pad counts, all with a mean age of 75 years. The overall AUASS, AUASS QOL, and overall M-ISI scores improved in 67.6, 54.8, and 61.3 % respectively (4.5 ± 7.9, 1.3 ± 1.7 and 5.5 ± 8.6 respectively). The M-ISI bother score improved in 44.8 % with a mean improvement of 0.5 ± 2.9, but did not reach significance. There was a 1.7 ± 3.7 decrease in the mean number of pads used daily after the procedure (p = 0.006) and 19 % experienced transient urinary retention.

Conclusions

Peri-urethral calcium hydroxylapatite injections can improve urinary QOL scores in patients with initial and recurrent stress urinary incontinence. This short-term retrospective analysis suggests that larger long-term studies focusing on QOL outcomes are needed to evaluate the effect of peri-urethral calcium hydroxylapatite has on incontinence-specific QOL.

Available only for authorised users

Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, Spino C, Whitehead WE, Wu J, Brody DJ, Pelvic Floor Disorders Network (2008) Prevalence of symptomatic pelvic floor disorders in US women. JAMA 300:1311–1316. doi:10.1001/jama.300.11.1311 CrossRefPubMedPubMedCentral

Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R, Bump RC (2003) Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 189:1275–1282. doi:10.1067/s0002-9378(03)00598-2 CrossRefPubMed

Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW (1997) Definition of overactive bladder and epidemiology of urinary incontinence. Urology 50:4–14. doi:10.1016/s0090-4295(97)00578-5 CrossRefPubMed

U.S. Food and Drug Administration. Urogynecologic surgical mesh: update on the safety and effectiveness of transvaginal placement for pelvic organ prolapse. Silver Spring, MD: U.S. Food and Drug Administration; 2011. http://www.fda.gov/downloads/medicaldevices/safety/alertsandnotices/UCM262760.pdf. Accessed 14 January 2013

Committee on Gynecologic Practice, American Urogynecologic Society (2014) Committee opinion No. 603: evaluation of uncomplicated stress urinary incontinence in women before surgical treatment. Obstet Gynecol 123:1403–1407. doi:10.1097/01.AOG.0000450759.34453.31 CrossRef

Zoorob D, Karram M (2012) Bulking agents: a urogynecology perspective. Urol Clin North Am 39:273–277. doi:10.1016/j.ucl.2012.06.012 CrossRefPubMed

Davis NF, Kheradmand F, Creagh T (2013) Injectable biomaterials for the treatment of stress urinary incontinence: their potential and pitfalls as urethral bulking agents. Int Urogynecol J 24:913–919. doi:10.1007/s00192-012-2011-9 CrossRefPubMed

Mayer RD, Dmochowski RR, Appell RA, Sand PK, Klimberg IW, Jacoby K, Graham CW, Snyder JA, Nitti VW, Winters JC (2007) Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology 69:876–880. doi:10.1016/j.urology.2007.01.050 CrossRefPubMed

Suskind AM, Dunn RL, Morgan DM, DeLancey JO, Rew KT, Wei JT (2015) A screening tool for clinically relevant urinary incontinence. Neurourol Urodyn 34:332–335. doi:10.1002/nau.22564 CrossRefPubMed

10.

Chai TC, Belville WD, McGuire EJ, Nyquist L (1993) Specificity of the American urological association voiding symptom index: comparison of unselected and selected samples of both sexes. J Urol 150:1710–1713PubMed

11.

Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol 148:1549–1557PubMed

12.

Gumus II, Kaygusuz I, Derbent A, Simavli S, Kafali H (2011) Effect of the Macroplastique implantation system for stress urinary incontinence in women with or without a history of an anti-incontinence operation. Int Urogynecol J 22:743–749. doi:10.1007/s00192-011-1398-z CrossRefPubMed

13.

Lose G, Sorensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T (2010) An open multicenter study of polyacrylamide hydrogel (Bulkamid(R)) for female stress and mixed urinary incontinence. Int Urogynecol J 21:1471–1477. doi:10.1007/s00192-010-1214-1 CrossRefPubMedPubMedCentral

14.

Lee HN, Lee YS, Han JY, Jeong JY, Choo MS, Lee KS (2010) Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures. Int Urogynecol J 21:1479–1483. doi:10.1007/s00192-010-1224-z CrossRefPubMed

15.

Ghoniem G, Corcos J, Comiter C, Westney OL, Herschorn S (2010) Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol 183:1444–1449. doi:10.1016/j.juro.2009.12.038 CrossRefPubMed

16.

Ghoniem G, Corcos J, Comiter C, Bernhard P, Westney OL, Herschorn S (2009) Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol 181:204–210. doi:10.1016/j.juro.2008.09.032 CrossRefPubMed

Title: Quality of life outcomes in peri-urethral calcium hydroxylapatite injection
Authors: Meghan A. Griffin
Kirsten J. C. Janosek-Albright
Mireya Diaz-Insua
Solafa Elshatanoufy
Humphrey O. Atiemo
Publication date: 01-12-2016
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 12/2016
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-016-3053-1

At a glance: The STEP trials

Springer Medicine

Quality of life outcomes in peri-urethral calcium hydroxylapatite injection

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2016

Aggressive angiomyxoma presenting as massive irreducible vaginal prolapse

Prevention of pelvic floor disorders: international urogynecological association research and development committee opinion

The pelvic floor muscle training manoeuvre works by increasing intraurethral resistance. Comment on “Influence of voluntary pelvic floor muscle contraction and pelvic floor muscle training on urethral closure pressures: a systematic literature review”

Female pelvic organ prolapse using pessaries: systematic review

A retrospective comparison of two vaginal mesh kits in the management of anterior and apical vaginal prolapse: long-term results for apical fixation and quality of life

Reply to the letter to the editor on Prien-Larsen et al.: Influence of TVT properties of midurethral sling procedures: high-stiffness versus low-stiffness tape